- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03156361
21 Day Comparison of Continuous Insulin Infusion Using HDV Insulin to Standard Insulin in Type 1 Diabetes Mellitus
A Randomized Controlled Trial Comparing 21 Days of Continuous Subcutaneous Insulin Infusion (CSII) Using Hepatic Directed Vesicle (HDV) Insulin to Standard CSII in Type 1 Diabetes Mellitus
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a single center, double blind, active comparator controlled 2-Way crossover multiple dose safety, tolerability and efficacy study.
The study will consist of three periods. Total duration will be approximately nine weeks, including a screening period of up to 14 days, a 7-day run-in period and two 21-day treatment periods.
Subjects will be screened and then they will undergo a week of baseline CGM. They will then be randomized to one of two treatment sequences: three weeks of treatment with HDV-lispro followed by three weeks of treatment with insulin lispro diluted with sterile water to match the insulin concentration in HDV-lispro, or the same treatments in the reverse order.
A test meal study (standardized liquid test meal) is to be conducted at the beginning of treatment (baseline study) and at the end of each three week treatment period. As noted above, frequent blood samples will be collected for glucose and insulin levels during the first (baseline study) test meal; during the two test meals performed after the two treatment periods the same sampling for glucose and insulin will be performed, with the addition of collecting samples for glucagon levels.
Subjects will also perform blinded continuous glucose monitoring throughout the entirety of the study (7 weeks).
Throughout study, subjects will be asked to perform frequent self-monitoring of blood glucose (SMBG), at least 6 times per day (before and 60-90 minutes after each meal) during 3 or more days of each week. This will serve as data for therapeutic decision-making as well as for data collection.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Georgia
-
Atlanta, Georgia, United States, 30318
- Atlanta Diabetes Association
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- T1DM ≥12 months
- C-peptide <0.6 ng/mL (a single re-test is allowable)
- Treatment with rapid analog insulin by CSII for the previous 6 months
- Familiarity with continuous glucose monitoring (CGM) technology; subjects nee d not be currently using CGM but should have used it in the past. Personal (unblinded) CGM will NOT be allowed during the study
- Willingness to use insulin lispro as the analog insulin during the study period
- Use of MiniMed Paradigm® pump for the previous 6 months. Pumps that employ low glucose suspend technology will NOT be allowed during the study
- BMI ≥18.0 kg/m2 and ≤35.0 kg/m2
- A1C≤9.0% (a single re-test is allowable)
Exclusion Criteria:
- Known or suspected allergy to any component of any of the study drugs in this trial.
- A patient who has unstable proliferative retinopathy or maculopathy, and/or severe neuropathy, in particular autonomic neuropathy, as judged by the Investigator.
- Use of oral anti-diabetic or non-insulin anti-diabetic injection therapies (e.g. SGLT-2 inhibitors, pramlintide, GLP-1 agonists, etc.)
- Current smokers; if a former smoker, no tobacco products (inhaled, oral or buccal) for the previous 3 months
- As judged by the investigator, clinically significant active disease of the gastrointestinal, cardiovascular (including a history of arrhythmia or conduction delays on ECG), hepatic, neurological, renal, genitourinary, or hematological systems, or uncontrolled hypertension (diastolic blood pressure ≥ 100 mmHg and/or systolic blood pressure ≥ 160 mmHg after 5 minutes in the supine position).
- History of any illness or disease that in the opinion of the Investigator might confound the results of the trial or pose additional risk in administering the study drugs to the patient.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: HDV insulin lispro 100 UNIT/mL
Hepatic Directed Vesicle (HDV) is the active excipient, added to insulin lispro.
HDV binds to a portion of the insulin lispro.
|
Hepatic Directed Vesicle (HDV) added to commercial insulin lispro
Other Names:
|
ACTIVE_COMPARATOR: Insulin Lispro 100 UNIT/mL
Sterile Water for Injection (SWFI) is added to the insulin lispro, to dilute the insulin lispro equal to the HDV insulin lispro
|
Sterile Water for Injection added to commercial insulin lispro
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Glucose area under the curve
Time Frame: 21 days
|
To evaluate glucose response (incremental AUC) to standardized test meal challenge following 21 days of CSII treatment with HDV insulin lispro versus insulin lispro diluted with sterile water
|
21 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
total units Insulin
Time Frame: 21 days
|
To compare insulin doses (basal, bolus and total) during HDV insulin lispro treatment
|
21 days
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Director: Douglas Muchmore, MD, Diasome Pharmaceuticals
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- DP 01-2017-02
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type1 Diabetes Mellitus
-
Joslin Diabetes CenterCambridge Medical Technologies, LLCCompletedType 2 Diabetes Mellitus | Type1 Diabetes MellitusUnited States
-
Yale UniversityNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)TerminatedType1 Diabetes MellitusUnited States
-
Massachusetts General HospitalCompletedType1 Diabetes MellitusUnited States
-
Universidad Loyola AndaluciaUnknown
-
Jessa HospitalCompleted
-
Eli Lilly and CompanyCompletedA Study of an Automated Insulin Delivery System in Participants With Type 1 Diabetes Mellitus (T1DM)Type1 Diabetes MellitusUnited States
-
AdociaCompleted
-
Second Xiangya Hospital of Central South UniversityRecruitingType1 Diabetes Mellitus | Autoimmune DiabetesChina
-
Chinese University of Hong KongRecruiting
-
REMD Biotherapeutics, Inc.CompletedType1 Diabetes MellitusUnited States
Clinical Trials on HDV insulin lispro 100 UNIT/mL
-
Diasome PharmaceuticalsIntegriumCompletedDiabetes Mellitus, Type 1United States
-
Diasome Pharmaceuticlas, Inc.RecruitingDiabetes Mellitus, Type 1United States
-
Diasome PharmaceuticalsIntegriumCompletedType 1 Diabetes MellitusUnited States
-
Diasome PharmaceuticalsCompletedDiabetes Mellitus, Type 1United States
-
University of California, San DiegoThe Leona M. and Harry B. Helmsley Charitable TrustNot yet recruiting
-
Stanford UniversityUniversity of Colorado, Denver; BiodelWithdrawnDiabetes MellitusUnited States
-
Dance Biopharm Inc.Profil Institut für Stoffwechselforschung GmbHCompletedType 2 Diabetes MellitusGermany
-
Dance Biopharm Inc.WCCT GlobalTerminatedSafety and TolerabilityUnited States
-
AstraZenecaJuvenile Diabetes Research FoundationCompletedType 1 Diabetes MellitusUnited States